Labor Induction Clinical Trial
— BALIOfficial title:
BMI-Associated Labor Induction: A Prospective Trial
The primary objective of this study is to determine if planned induction of labor at 39 weeks for nulliparous with pre-pregnancy BMI ≥ 35 kg/m2 reduces the incidence of cesarean section compared to expectant management
Status | Recruiting |
Enrollment | 82 |
Est. completion date | December 31, 2022 |
Est. primary completion date | September 30, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age 18 years and older 2. Pregnant, singleton gestation, vertex presentation 3. Nulliparous (no prior pregnancy delivered past 20 weeks) 4. Pre-pregnancy (self-reported in record of in EMR within 3 months of LMP) or 1st trimester (up to and including 14 weeks 0 days) BMI = 35 kg/m2 5. Gestational age at enrollment 38 weeks 0 days and 38 weeks 6 days with dating confirmed by LMP and ultrasound performed prior to 20 6/7 weeks Exclusion Criteria: 1. Plan for induction of labor prior to 41 weeks 0 days for medical indication prior to study consideration 2. Plan for cesarean delivery or contraindication to labor 3. Major illness with increased risk of adverse pregnancy outcomes (e.g. pregestational diabetes with or without medication, gestational diabetes on medication, hypertension, cardiac disease, renal insufficiency, autoimmune disorder) 4. Multiple gestation 5. Non-vertex presentation 6. Fetal death 7. Fetus with major/lethal anomaly or aneuploidy (soft markers of aneuploidy, urinary tract dilation, isolated bowel dilation, mild ventriculomegaly, normal variants of vascular system, and isolated ventricular septal defects will not be excluded) a. Soft markers not qualifying as exclusion criteria: echogenic intracardiac focus, choroid plexus cyst, echogenic bowel, increased NT or nuchal fold, isolate short humerus or femur 8. Fetal growth restriction (EFW <10th percentile or AC <10th percentile) 9. Preeclampsia or gestational hypertension 10. Known oligohydramnios or polyhydramnios 11. Prior delivery after 20 weeks 12. Placenta/vasa previa 13. Placental abruption (known or suspected) or unexplained vaginal bleeding 14. Previous cesarean section, myomectomy, or classical cesarean 15. Spontaneous labor or suspicion of labor with regular contractions and cervical change, rupture membranes 16. Active genital herpes or HIV positive 17. Inability to consent 18. Any contraindication to a vaginal delivery 19. Delivery anticipated outside of Baystate Medical Center |
Country | Name | City | State |
---|---|---|---|
United States | Sidney Kimmel Medical College, Thomas Jefferson University | Philadelphia | Pennsylvania |
United States | Baystate Medical Center | Springfield | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Baystate Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of cesarean section | The primary outcome is to determine whether planned induction of labor at 39 weeks for obese nulliparous women changes the incidence of cesarean section. | Admission for induction to discharge from delivery admission, up to 3 weeks after enrollment. | |
Secondary | Incisional extensions at cesarean section | J or T shape incisions or cervical trauma | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Operative vaginal delivery and indication | Vacuum or forceps | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Suspected intraamniotic infection | At least one maternal fever =100.4 F with at least one additional clinical sign of maternal tachycardia, fetal tachycardia, uterine tenderness or purulent/foul smelling vaginal discharge | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | 3rd or 4th degree perineal laceration | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Maternal death | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Antepartum, intrapartum, or neonatal death | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Admission to the intensive care unit (ICU) | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Preeclampsia | Preeclampsia without severe features: Elevated blood pressure after 20 weeks =140/90 on 2 occasions at least 4 hours apart with previously normal blood pressure AND,
proteinuria (=300 mg per 24 hours collection OR =0.3 mg/dL on protein:creatinine ratio OR 1+ on dipstick if neither of the previous is available) Preeclampsia with severe features: Elevated blood pressure after 20 weeks =160/110 on 2 occasions (may be within minutes to ensure medication treatment) OR, Blood pressure =140/90 and systemic findings including: new platelet count <100,000microliter, serum creatinine >1.1 mg/dL, doubling of serum creatinine in absence of other renal disease, liver transaminases twice upper limit of normal, pulmonary edema, cerebral or visual symptoms Proteinuria is not necessary for this diagnosis Eclampsia: preeclampsia with eclamptic seizure |
From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Gestational hypertension | Gestational hypertension: blood pressure elevation =140/90 on two occasions after 20 weeks in absence of proteinuria or systemic findings defined above | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Postpartum hemorrhage | Visual estimated blood loss >1000 mL or need for two or more uterotonics | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Postpartum endometritis | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Composite maternal infectious outcome | Endometritis, wound reopened for hematoma, seroma, infection, or other reasons, cellulitis requiring antibiotics, pneumonia, pyelonephritis, bacteremia of unknown source, septic pelvic thrombosis | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Maternal venous thromboembolism | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Birth weight | Macrosomia >4500 grams, large for gestational age (LGA) defined as 90th percentile weight for gestational age, assessed specifically by sex and race of the infant based on United States birth certificate data | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Duration and presence (up to 72 hours) of respiratory support | Including ventilator, CPAP, high-flow nasal cannula (HFNC) | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Small for gestational age | <5th percentile and <10th percentile weight for gestational age, assessed specifically by sex and race of the infant based on United States birth certificate data | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Cephalohematoma | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Shoulder dystocia | Need for additional maneuvers to accomplish delivery | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Transfusion of blood products | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Breastfeeding intention and initiation in the hospital | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Breastfeeding at 6 weeks (exclusive and any breastfeeding) | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Hyperbilirubinemia requiring phototherapy or exchange transfusion | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Apgar = 7 at 5 minutes | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Neonatal seizures | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Sepsis | Requires the presence of a clinically ill infant in whom systemic infection is suspected with a positive blood, cerebrospinal fluid (CSF), or catheterized/suprapubic urine culture; or, in the absence of positive cultures, clinical evidence of cardiovascular collapse or an unequivocal X-ray confirming infection. | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Neonatal encephalopathy | As defined by Shankaran et al. | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Meconium aspiration syndrome | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Birth trauma | Bone fractures, brachial plexus palsy, other neurologic injury, retinal hemorrhage facial nerve injury | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Intracranial hemorrhage or subgaleal hemorrhage | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Neonatal hypotension requiring pressor support | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Neonatal composite outcome | IUFD, neonatal death, intubation or neonatal respiratory support, Apgar score = 7 at 5 minutes, seizures, sepsis as defined above, neonatal encephalopathy, pneumonia, meconium aspiration syndrome, birth trauma, intracranial hemorrhage, or hypotension | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Hypoglycemia | glucose < 35 mg/dL requiring IV therapy | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | |
Secondary | Admission to the neonatal intensive care unit (NICU) | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Number of clinic visits post enrollment to admission for delivery | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Non-stress tests, biophysical profiles (BPP), modified BPPs, ultrasounds done other than BPP, Doppler, contraction stress test | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Intrauterine pressure catheter (IUPC) or fetal scalp electrode placement | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Epidural use | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Use of induction and ripening agents, maximum dose of oxytocin | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Number of hours on labor and delivery unit | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Maternal postpartum length of hospital stay | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Neonatal length of hospital stay | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Length of NICU or intermediate care stay | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. | ||
Secondary | Post discharge resource utilization | Inpatient and outpatient visits for mother and baby from discharge to 6 weeks | From enrollment to 6-8 weeks postpartum, average of 10 weeks after enrollment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00141895 -
A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death
|
Phase 3 | |
Completed |
NCT03039036 -
Early Amniotomy Versus Delayed Amniotomy Following Foley Catheter Ripening in Nulliparous Labor Induction
|
N/A | |
Completed |
NCT05827731 -
Cervical Double Balloon Combined With Oxytocin
|
N/A | |
Withdrawn |
NCT00771511 -
Cervical Capsaicin for Labor Induction and Pain Relief
|
Phase 4 | |
Recruiting |
NCT04075630 -
Observatory on Artificial Labour-induction Methods and Measuring Immediate Postpartum Maternal Satisfaction
|
||
Active, not recruiting |
NCT04573517 -
Early Amniotomy Following Transcervical Foley Balloon in the Induction of Labor
|
N/A | |
Withdrawn |
NCT05257187 -
Foley Catheter Induction
|
N/A | |
Recruiting |
NCT03016442 -
Dinoprostone Vaginal Insert Versus Double Balloon Catheter for Preinduction Cervical Ripening
|
Phase 2 | |
Not yet recruiting |
NCT00984347 -
Breast Stimulation Versus Pitocin for Induction of Labor
|
N/A | |
Completed |
NCT04596397 -
Oral Misoprostol for Outpatient Induction of Labor
|
N/A | |
Completed |
NCT03504670 -
Preterm Induction of Labor Timing of Amniotomy: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT00886860 -
The Comparison of Efficacy for Cervical Ripening in Labor Induction Between Titrated and Conventional Oral Misoprostol
|
Phase 4 | |
Completed |
NCT00504465 -
Combined Agent Randomized Trial of Induction of Labor
|
N/A | |
Completed |
NCT01402050 -
Foley Catheter Versus Cervidil for Induction of Labor at Term
|
N/A | |
Completed |
NCT01170819 -
Double Balloon Catheter Versus Dinoprostone Vaginal Insert for Cervical Ripening.
|
Phase 4 | |
Completed |
NCT00529295 -
Titrated Oral Compared With Vaginal Misoprostol for Labor Induction at Term
|
Phase 3 | |
Completed |
NCT00346840 -
Safety and Efficacy Study of Misoprostol Vaginal Insert for Induction of Labour
|
Phase 2 | |
Completed |
NCT00442663 -
Trial of Foley Catheter With and Without Extra-Amniotic Saline Infusion for Labor Induction
|
N/A | |
Withdrawn |
NCT03218735 -
Early Term Delivery Versus Expectant Management of the Large for Gestational Age Fetus
|
N/A | |
Completed |
NCT02639429 -
Cervical Ripening for Obese Women: A Randomized, Comparative Effectiveness Trial
|
Phase 4 |